Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by D.B. Root & Company LLC

D.B. Root & Company LLC decreased its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 2.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,082 shares of the pharmaceutical company’s stock after selling 27 shares during the quarter. D.B. Root & Company LLC’s holdings in Vertex Pharmaceuticals were worth $482,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC raised its stake in shares of Vertex Pharmaceuticals by 15.0% during the fourth quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company’s stock worth $1,783,000 after purchasing an additional 579 shares during the last quarter. NBC Securities Inc. purchased a new position in Vertex Pharmaceuticals in the first quarter worth $167,000. RFG Advisory LLC raised its position in Vertex Pharmaceuticals by 12.1% in the first quarter. RFG Advisory LLC now owns 757 shares of the pharmaceutical company’s stock worth $367,000 after acquiring an additional 82 shares in the last quarter. SeaCrest Wealth Management LLC purchased a new position in Vertex Pharmaceuticals in the first quarter worth $370,000. Finally, Pines Wealth Management LLC purchased a new position in Vertex Pharmaceuticals in the first quarter worth $205,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Down 1.4%

NASDAQ:VRTX opened at $403.30 on Monday. The stock has a fifty day simple moving average of $399.12 and a 200 day simple moving average of $442.02. The firm has a market capitalization of $103.40 billion, a price-to-earnings ratio of 28.83 and a beta of 0.43. Vertex Pharmaceuticals Incorporated has a 1-year low of $362.50 and a 1-year high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, topping analysts’ consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The firm had revenue of $2.94 billion during the quarter, compared to analyst estimates of $2.90 billion. During the same period last year, the company posted ($12.83) EPS. The business’s quarterly revenue was up 11.3% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have issued reports on VRTX. Truist Financial set a $490.00 price objective on Vertex Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, August 5th. BMO Capital Markets set a $530.00 target price on Vertex Pharmaceuticals and gave the company an “outperform” rating in a report on Tuesday, August 5th. Raymond James Financial initiated coverage on Vertex Pharmaceuticals in a report on Tuesday, September 2nd. They issued a “market perform” rating on the stock. UBS Group set a $553.00 target price on Vertex Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, August 5th. Finally, Evercore ISI lowered their target price on Vertex Pharmaceuticals from $510.00 to $475.00 and set an “outperform” rating on the stock in a report on Thursday, September 11th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and twelve have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $493.81.

Insider Buying and Selling at Vertex Pharmaceuticals

In related news, Director Bruce I. Sachs acquired 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 6th. The shares were acquired at an average cost of $389.68 per share, with a total value of $1,948,400.00. Following the purchase, the director owned 45,000 shares of the company’s stock, valued at approximately $17,535,600. The trade was a 12.50% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.